Oncopeptides publishes the 2020 Annual Report

Rhea-AI Summary

Oncopeptides AB published its 2020 Annual Report, highlighting significant advancements in R&D, organizational capabilities, and sustainability despite pandemic challenges. Key achievements include the FDA granting priority review for melflufen in treating triple-class refractory multiple myeloma, leading to the drug's accelerated approval and launch in the U.S. in early 2021. The report underscores the company's growth trajectory and commitment to developing targeted therapies for hematological diseases, utilizing its proprietary peptide-drug conjugate platform.

Positive

• FDA granted priority review for melflufen, leading to accelerated approval and U.S. launch of PEPAXTO.
• Significant advancements in R&D and organizational capabilities.
• Successful delivery on all major milestones despite pandemic challenges.

Negative

• None.

STOCKHOLM, April 26, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today publishes the 2020 Annual Report.

The report summarizes an extraordinary year in the Company´s proud history, with significant advancements in the Research and Development programs, organizational capabilities, strategic direction, company culture and sustainability. Oncopeptides delivered on all major milestones, despite the challenging conditions caused by the ongoing global pandemic.

"The past year has been a transformational year for Oncopeptides highlighted by the FDA decision to grant our NDA submission of melflufen in triple class refractory multiple myeloma a priority review, leading to the accelerated approval and commercial launch of PEPAXTO^® in the U.S. early 2021", says Marty J Duvall, Chief Executive Officer at Oncopeptides AB. Not many emerging biotech companies cross the finish line in terms of launching a product that can make a significant difference for patients".

The 2020 Annual Report is available in a pdf format, and in a digital version on www.oncopeptides.com.

For more information, please contact:

Rolf Gulliksen, Global Head of Corporate Communications, Oncopeptides AB
E-mail: rolf.gulliksen@oncopeptides.com
Cell phone: + 46 70 262 96 28

Linda Holmström, Director of Investor Relations, Oncopeptides AB
E-mail: linda.holmstrom@oncopeptides.com  
Cell phone: +46 70 873 40 95

About Oncopeptides

Oncopeptides is a global biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company uses its proprietary peptide-drug conjugate (PDC) platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. The first drug stemming from the PDC platform, PEPAXTO® (melphalan flufenamide), has been launched in the U.S., for the treatment of adult patients with relapsed or refractory multiple myeloma. Melphalan flufenamide is evaluated in a comprehensive clinical study program including the global phase 3 studies OCEAN and LIGHTHOUSE. Oncopeptides is developing several new compounds which are based on the PDC platform. The first one is expected to enter into clinical development in 2021.

Oncopeptides has approximately 300 coworkers. The global Headquarters is based in Stockholm, Sweden and the U.S. Headquarters is situated in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. More information is available on www.oncopeptides.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/oncopeptides-ab/r/oncopeptides-publishes-the-2020-annual-report,c3333385

The following files are available for download:

https://mb.cision.com/Main/15404/3333385/1407338.pdf	Oncopeptides AB (publ) Annual Report 2020 (English)
https://mb.cision.com/Main/15404/3333385/1407339.xhtml	Oncopeptides Annual Report 556596-6438_2020.xhtml
https://mb.cision.com/Public/15404/3333385/ab957fda6c42d88f.pdf	Press release - Publication of Oncopeptides AB publ Annual report 2020

 

View original content:http://www.prnewswire.com/news-releases/oncopeptides-publishes-the-2020-annual-report-301276694.html

SOURCE Oncopeptides AB

FAQ

What are the key highlights from Oncopeptides' 2020 Annual Report?

Oncopeptides' 2020 Annual Report highlights include FDA priority review for melflufen, advancements in R&D, and successfully meeting all major milestones.

When was PEPAXTO launched in the U.S.?

PEPAXTO was commercially launched in the U.S. in early 2021 following its accelerated approval by the FDA.

What challenges did Oncopeptides overcome in 2020?

Oncopeptides overcame significant challenges posed by the global pandemic while achieving major advancements in their operations and drug development.

What is the focus of Oncopeptides as a biotech company?

Oncopeptides focuses on developing targeted therapies for difficult-to-treat hematological diseases using their proprietary peptide-drug conjugate platform.